Barbara Botto

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

Patrizia Pregno, Annalisa Chiappella, Marilena Bellò et al. · Blood · 2012 · 234 citations

⁹⁰Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial

Franck Morschhauser, John Radford, Achiel Van Hoof et al. · Journal of Clinical Oncology · 2013 · 203 citations

Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia.

Daniela Capello, Umberto Vitolo, Laura Pasqualucci et al. · PubMed · 2000 · 200 citations

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

Umberto Vitolo, Annalisa Chiappella, Silvia Franceschetti et al. · The Lancet Oncology · 2014 · 182 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

Luca Ceriani, Maurizio Martelli, Pier Luigi Zinzani et al. · Blood · 2015 · 171 citations · Full text